Deloitte China assists listing of Ab&B Bio-Tech on SEHK
Biotech listing with highest public subscription so far in 2025
Deloitte China supported the listing of Ab&B Bio-Tech CO. (Ab&B Bio-Tech, stock ticker: 02627.HK) on the Stock Exchange of Hong Kong (SEHK) on 11 August 2025.
Ab&B Bio-Tech offered around 33.44 million shares at HKD12.9 per share, with gross proceeds amounting to about HKD431 million.
(From left) Sigrid Sun, Deloitte China’s Audit & Assurance (A&A) senior auditor; Peter Tao, A&A manager; Jenny Chen, A&A senior manager; Molly Bao and Bobby Yu, Capital Market Services Group’s Eastern Region Offering Services partners, attend Ab&B Bio-Tech’s listing ceremony at SEHK.
(From left) Sigrid Sun; Peter Tao; Bobby Yu; Lisa Li, CFO of Ab&B Bio-Tech; Youcai An, chairman of the Board and general manager of Ab&B Bio-Tech; Ernest Lee, Technical partner and a member of the Listing Committee of the SEHK; Molly Bao and Jenny Chen attend the listing ceremony at SEHK.
Client overview
Ab&B Bio-Tech was founded in 2015 and is dedicated to the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines utilising new technology. As of 21 July 2025, Ab&B Bio-Tech had
- two core products, the quadrivalent subunit influenza vaccine, which was approved by the National Medical Products Administration of the PRC (NMPA) for individuals aged three years and above under the brand name Huierkangxin (慧尔康欣) in May 2023, a lyophilized (freeze-dried) human rabies vaccine candidate, which is developed using human diploid cells; and
- 11 other vaccine candidates covering various disease areas with considerable needs for vaccination.
Source: Ab&B Bio-Tech IPO prospectus published on 31 July 2025
Deloitte’s role
As a core service institution for this new listing engagement, Deloitte China was deeply involved in the entire process of application and listing of this client. This successful listing demonstrates Deloitte's professional service capabilities in serving clients in capital markets.
Ab&B Bio-Tech started its Hong Kong IPO on the Main Board of the SEHK in October 2024. Our engagement team worked closely with various professional parties, provided high-quality services with rich industry experience and excellent professional capabilities and assisted Ab&B Bio-Tech in successfully submitting its listing application form to the SEHK in January 2025. It passed the hearing in July 2025 and listed on the Main Board of the SEHK in August 2025. It took only 10 months from the commencement of the IPO engagement work to the listing.
Deloitte China congratulates Ab&B Bio-Tech on its successful listing on the SEHK. We will continue to provide high quality professional services and outstanding resources integration to assist more clients to take one-step ahead in today's increasingly competitive and complex business environment.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see About Deloitte to learn more.
Deloitte China provides integrated professional services, with our long-term commitment to be a leading contributor to China’s reform, opening-up and economic development. We are a globally connected firm with deep roots locally, owned by our partners in China. With over 20,000 professionals across 31 Chinese cities, we provide our clients with a one-stop shop offering world-leading audit, tax and consulting services.
We serve with integrity, uphold quality and strive to innovate. With our professional excellence, insight across industries, and intelligent technology solutions, we help clients and partners from many sectors seize opportunities, tackle challenges and attain world-class, high-quality development goals.
The Deloitte brand originated in 1845, and its name in Chinese (德勤) denotes integrity, diligence and excellence. Deloitte's global professional network of member firms now spans more than 150 countries and territories. Through our mission to make an impact that matters, we help reinforce public trust in capital markets, enable clients to transform and thrive, empower talents to be future-ready, and lead the way toward a stronger economy, a more equitable society and a sustainable world.
This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited (“DTTL”), its global network of member firms or their related entities (collectively, the “Deloitte organization”) is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.
No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities.
